STAINES-UPON-THAMES, United Kingdom, Aug. 22, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, confirmed today that it has received a Complete Response Letter from the U.S. Food and Drug…Original Article
Mallinckrodt Confirms Receipt of Stannsoporfin Complete Response Letter
